EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Mass Spectrometry‐Based Proteomics for Next‐Generation Precision Oncology

Kuen-Tyng Lin iD, Gul Muneer, Pei-Rong Huang, Ciao-Syuan Chen, Yu-Ju Chen iD

Mass Spectrometry Reviews · 2026-03 · 45 (2) · 361-391

DOI: 10.1002/mas.21932 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Mass Spectrometry Reviews, online erschienen am 23.04.2025. Verfasst von Kuen-Tyng Lin und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Chemistry, Academia Sinica, Taipei, Taiwan. Hauptthemen laut MEDLINE: Proteomics, Precision Medicine, Mass Spectrometry, Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 284 Literaturangaben. Gefördert von: This study was supported and funded by the Next-Generation Pathway of Taiwan Cancer Precision Medicine Program (AS-KPQ-107-TCPMP), National Science and Technol…, Academia Sinica, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer is the leading cause of death worldwide characterized by patient heterogeneity and complex tumor microenvironment. While the genomics‐based testing has transformed modern medicine, the challenge of diverse clinical outcomes highlights unmet needs for precision oncology. As functional molecules regulating cellular processes, proteins hold great promise as biomarkers and drug targets. Mass spectrometry (MS)‐based clinical proteomics has illuminated the molecular features of cancers and facilitated discovery of biomarkers or therapeutic targets, paving the way for innovative strategies that enhance the precision of personalized treatment. In this article, we introduced the tools and current achievements of MS‐based proteomics, choice of discovery and targeted MS from discovery to validation phases, profiling sensitivity from bulk samples to single‐cell level and tissue to liquid biopsy specimens, current regulatory landscape of MS‐based protein laboratory‐developed tests (LDTs). The challenges, success and future perspectives in translating research MS assay into clinical applications are also discussed. With well‐designed validation studies to demonstrate clinical benefits and meet the regulatory requirements for both analytical and clinical performance, the future of MS‐based assays is promising with numerous opportunities to improve cancer diagnosis, treatment, and monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsPrecision MedicineMass SpectrometryNeoplasmsHumansBiomarkers, TumorMedical Oncology

Stichwörter der Autor:innen

biomarkerlaboratory developed tests (LDTs)mass spectrometryprecision oncologyproteomicssingle‐cell proteomics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Institute of Chemistry, Academia Sinica, Taipei, Taiwan.
  • Department of Chemistry, National Taiwan University, Taipei, Taiwan.

ORCID-Profile: Kuen-Tyng Lin, Yu-Ju Chen

Förderung

  • This study was supported and funded by the Next-Generation Pathway of Taiwan Cancer Precision Medicine Program (AS-KPQ-107-TCPMP), National Science and Technol…
  • Academia Sinica
  • National Science and Technology Council

Zitieren

APA

Lin, K. T., Muneer, G., Huang, P. R., Chen, C. S., & Chen, Y. J. (2026). Mass Spectrometry‐Based Proteomics for Next‐Generation Precision Oncology. Mass Spectrometry Reviews, 45(2), 361-391. https://doi.org/10.1002/mas.21932

Vancouver

Lin KT, Muneer G, Huang PR, Chen CS, Chen YJ. Mass Spectrometry‐Based Proteomics for Next‐Generation Precision Oncology. Mass Spectrometry Reviews. 2026;45(2):361-391. doi:10.1002/mas.21932

BibTeX
@article{Lin2026,
  author = {Lin, Kuen-Tyng and Muneer, Gul and Huang, Pei-Rong and Chen, Ciao-Syuan and Chen, Yu-Ju},
  title = {Mass Spectrometry‐Based Proteomics for Next‐Generation Precision Oncology},
  journal = {Mass Spectrometry Reviews},
  year = {2026},
  volume = {45},
  number = {2},
  pages = {361--391},
  doi = {10.1002/mas.21932}
}
Kostenlos starten →